The present study evaluates immunogenicity and protection potency of a codon-optimized GRA1 DNA vaccine, wild type GRA1 DNA vaccine and an adjuvanted recombinant GRA1 protein vaccine candidate in BALB/c mice against lethal toxoplasmosis. Of the three GRA1 vaccines tested, the recombinant GRA1 protein vaccine results reveal significant increase in immune response and prolonged survival against acute toxoplasmosis compared to DNA vaccinations. Immune response and protection conferred by codon-optimized GRA1 DNA vaccine was slightly better than wild type GRA1 DNA vaccine.
Introduction
Toxoplasma gondii is one of the most successful protozoan parasites because it has a very broad host range, infecting all warm-blooded animals, including humans [1] and causes serious clinical presentations. There is no 100% effective drug to treat all clinical presentations of T. gondii. Available drugs have many side effects and reactivation may occur any time. The development of a vaccine, which can prevent the consequences of acute infection, is therefore, an attractive alternative. After classification in category B bioterrorism agents as a food and water safety threat, the demand for a protective vaccine has increased [2] .
Vaccine strategies against toxoplasmosis aim to induce Th1 response and IFN-␥ production because immune protection against T. gondii in mice is primarily correlated with Th1 cell mediated immunity [3, 4] and IFN-␥ secretion [5] . Many attempts have been made to create an immunogenic protective vaccine against toxoplasmosis using mutant T. gondii strains, purified proteins, and DNA vaccines since 1990s [6] . The accumulated results suggest that a protective vaccine against T. gondii infection is feasible. Recombinant protein vaccines and DNA vaccines using Surface Antigen 1 (SAG1), SAG2, Dense Granule Antigen 1 (GRA1), GRA4, GRA7, Rhoptry Protein 2 (ROP2), Microneme Protein 3 (MIC3) and Heat Shock Protein 70 (HSP70) elicit partial, full, or occasionally no protection in animals depending on the virulence of the T. gondii strains . Of all the vaccine candidates against toxoplasmosis, GRA1 appears to be an immunogenic promising vaccine candidate [8, [26] [27] [28] 31] . Existing GRA1 vaccination trials used recombinant protein or DNA vaccines. Although immune response and protection potency have been investigated in detail about GRA1 DNA vaccination [26, 28] , the cellular immune response and protection potency of an adjuvanted recombinant GRA1 protein vaccine haven't been evaluated in mice yet [8, 27, 31] . Taken together, the experimental studies using various GRA1-derived vaccines are encouraging, however much work remains to put together the pieces of the puzzle, i.e. highlight the complexity of the immune response and the unpredictable relationships among various parameters such as vaccine strategy to be used against toxoplasmosis, protection and cellular immune response elicited by recombinant protein vaccine or parasite strain used to challenge the mice. In order to comprehensively evaluate these variables, the present study compares cellular immune response and protection potency of a recombinant GRA1 protein vaccine adjuvanted with a strong Th1 inducer Provax [32, 33] , a wild type GRA1 DNA vaccine and a GRA1 DNA vaccine codon-optimized for protein expression in mammalian cells. Codon usage optimization is widely accepted as a means of increasing the level of in vivo antigen expression from DNA vaccines and improving the cellular and humoral immune responses against the expressed antigens from diverse microorganisms [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . The codonoptimized GRA1 DNA vaccine used in this study is the first example of a codon-optimized gene being used as DNA vaccine candidate against T. gondii.
Materials and methods
Unless noted otherwise, all reagents were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
Mice
Female 6 week-old BALB/c mice were purchased from Charles River Laboratories Inc. (Wilmington, MA). Mice were housed and fed under standard, suitable conformist conditions. The experimental plan was performed under the instructions and approval of the Institutional Animal Care and Use Committee of UCI for animal ethics.
Parasites and preparation of T. gondii antigen
T. gondii RH strain tachyzoites were used to challenge the immunized mice and to prepare T. gondii antigen. RH strain tachyzoites were maintained in confluent monolayers of human foreskin fibroblasts (HFF) cell culture grown in Dulbeccos modified Eagle medium (DMEM) supplemented with 10% (v/v) heat inactivated fetal bovine serum (Hyclone, Logan, UT), 2 mM l-glutamine and 50 mg gentamycin per ml (Invitrogen-Gibco, Carlsbad, CA). T. gondii antigen (TAg) was prepared with the RH strain tachyzoites obtained from HFF cell culture as described [12] .
Computationally optimized DNA assembly (CODA) of the GRA1 gene
The GRA1 protein sequence from amino acid positions , excluding the signal peptide, was obtained from GENBANK database (accession number M26007), and submitted to CODA at the Computational Biology Research (CBR) Laboratory of the UC Irvine Institute for Genomics and Bioinformatics. The CODA algorithm generated a list of 36 linearly overlapping and abutting oligonucleotides, 39-64 nucleotides (nts) in length, optimized for self-assembly and expression of the codon-optimized GRA1 gene (co-GRA1) in mammalian cells. These oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA, USA).
Assembly of co-GRA1 intermediate DNA fragments
The full-length co-GRA1 DNA sequence was divided into three partially overlapping intermediate DNA fragments, each of which was subdivided into 12 short overlapping and abutting DNA oligonucleotides (intermediate fragment 0:237 bp; intermediate fragment 1:196 bp; intermediate fragment 2:196 bp). The co-GRA1 gene was assembled in two steps in which the DNA oligonucleotides were assembled first to form the three intermediate DNA fragments and then the intermediated fragments were mixed to form the full-length gene. For the assembly of each of the three intermediate DNA fragments of GRA1, the constituent DNA oligonucleotide set was added to a primer extension reaction at a final concentration of 0.1 M along with an excess (0.5 M) of leader and trailer primer oligonucleotides (the most 5 -and 3 -distant DNA oligonucleotides). The reactions included 2.5 U of PfuUltra High-Fidelity DNA polymerase (Stratagene, La Jolla, CA), 300 M dNTPs, and 1 × PfuUltra reaction buffer. The primer extension and PCR amplification reactions were performed in an Eppendorf Mastercycler (Hamburg, Germany) using the following calculated-control protocol: 5 min initial denaturation step at 95 • C, followed by 25 cycles of 20 s at 95 • C, 30 s at 62 • C, and 1 min at 72 • C, and an extension of 5 min at 72 • C. The PCR products were visualized by agarose gel electrophoresis.
TOPO PCR cloning
PCR product of each intermediate DNA fragment of the GRA1 gene was cloned into a pCRII-Blunt-TOPO vector according to the manufacturer's recommended protocol using One Shot electrocompetent Top 10 Escherichia coli cells (Invitrogen, Carlsbad, CA). The resulting plasmids, which contained intermediate DNA fragments of the correct size were visualized by agarose gel electrophoresis and purified for DNA sequencing using a plasmid mini purification kit according to the manufacturer's protocol (Aurum, Bio-Rad, Hercules, CA).
PCR assembly of full length co-GRA1
One of each sequence-verified intermediate DNA fragment of the GRA1 gene was isolated from the pCR-Blunt II TOPO vector by PCR amplification using the most 5 -and 3 -distant oligonucleotides for each intermediate DNA fragment. The amplification reactions included an excess of 0.25 M of leader and trailers, 2.5U of PfuUltra HighFidelity DNA polymerase (Stratagene), 150 M dNTPs, and 1 × PfuUltra reaction buffer. The PCR amplification reactions were performed using the following calculated-control protocol: 5 min initial denaturation step at 95 • C, followed by 25 cycles of 20 s at 95 • C, 1 min at 68 • C, and 1 min at 72 • C, and a final extension of 5 min at 72 • C. Subsequently, 1 l of each intermediate DNA fragment PCR product was combined with 1 M GRA1 gene leader (5 -most distant oligonucleotide of 45 nts and 1 M gene trailer (the 3 -most distant oligonucleotide of 44 nts) in another primer extension, using the same PCR amplification reaction defined above to generate the full-length co-GRA1 gene (531 bp). The PCR product visualization, TOPO PCR cloning and plasmid purification for DNA sequencing of the full-length co-GRA1 gene were performed as described above.
Cloning of wt-GRA1 and co-GRA1 into a mammalian expression vector
A cytomegalovirus (CMV) promoter containing mammalian expression vector (10 g; 5.1 kb; kanamycin resistant; Gene Therapy Systems, San Diego, CA) was linearized by BamHI as described [48] . The following primers were designed to generate a linear acceptor vector with sequences suitable for cloning by homologous recombination, 5 -CA-CCATCACCATCACCATCACCATCACGTCGAC-3 (forward primer, 33 nt), and 3 -TGATCTTTTATTAGCCAGAA-GTGATCTGGATCC-5 (reverse primer, 33 nt). During the PCR reaction an N-terminal polyhistidine tag was introduced to CMV vector immediately after the start codon, which was fused in frame with the ORF for purification and detection purposes. The linear acceptor vector was amplified as described [48] . The resulting linear CMV vector was used for in vivo recombination cloning.
PCR amplification of wt-GRA1 and co-GRA1
Wt-GRA1 and co-GRA1 were isolated from their recombinant plasmids with primers designed to incorporate adapter termini into the PCR product to facilitate directional cloning by homologous recombination ('HiRec') into the CMV vector. The primers for the wild type GRA1 were 5 -CA CCATCACCATCACCATCACCATCACGTCGACGCCG-AAGGCGGCGACAACCA-3 (forward primer, 53 nt; overlapping sequences, underlined) and 3 -TGATCTTTTATT-AGCCAGAAGTGAT CTGGATCCCTCTCTCTCTCCTG-TTAGGA-5 (reverse primer, 56 nt; overlapping sequences, underlined). The primers for co-GRA1 were 5 -CACCAT-CACCATCACCATCACCATCACGTCGACGCAGAGGG-AGGCGACAACCA-3 (forward primer, 53 nt; overlapping sequences, underlined) and 3 -TGATCTTTTATTAG-CCAGAAGTGATCTGGATCCCTCCCTCTCGCCGGTC-AGGA-5 (reverse primer, 56 nt; overlapping sequences, underlined). Co-GRA1 and wt-GRA1 genes were isolated from their template plasmids using the designed primers (0.5 M each), 2U of TaqDNA polymerase (Fisher Scientific), 150 M dNTPs and 1 × TaqDNA polymerase reaction buffer with the following calculated PCR protocol; 5 min initial denaturation step at 95 • C, followed by 30 cycles of 0.5 min at 95 • C, 0.5 min at 50 • C, and 3.5 min at 72 • C, and a final extension of 10 min at 72 • C. The PCR products were visualized by agarose gel electrophoresis, purified using a PCR purification kit (Qiagen) according to the manufacturer's protocol, and quantified by spectrophotometry.
In vivo recombination cloning method
In vivo recombination cloning was performed as described [48] . Briefly, the linear CMV vector, purified PCR product, and DH5␣ competent cells were mixed and heat shocked. Plasmids from overnight culture were purified using plasmid mini purification kit according to the manufacturer's protocol (Aurum, Bio-Rad) and visualized by agarose gel electrophoresis. The resulting plasmids containing wt-GRA1 and co-GRA1 were named CMV/wt-GRA1 and CMV/co-GRA1, respectively.
In vitro transfection of human embryonic kidney cells
Human embryonic kidney (HEK) 293 mammalian cells were obtained from the American Type Culture Collection (ATCC number: CRL-1573, Manassas, VA). HEK 293 cells were maintained in Dulbecco's modified eagle medium (DMEM), supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM l-glutamine, 100 IU of penicillin per ml, and 100 g of streptomycin per ml (Invitrogen-Gibco) at 5% CO 2 and 37 • C. Then HEK 293 cells were transfected with CMV/wt-GRA1 and CMV/co-GRA1 using Lipofectamine 2000 reagent according to the manufacturer's protocol (Invitrogen). HEK 293 cells transfected in four-well chamber slides were observed using monoclonal anti-polyhistidine antibody and immunofluorescence microscopy to determine the level of protein expression. In addition, the same HEK 293 cells, which were transfected in 10 cm-diameter culture dishes with the same protocol, were lysed to compare the protein expression using monoclonal anti-polyhistidine antibody and Western blotting.
Immunofluorescence
HEK 293 cells transfected with CMV/wt-GRA1 or CMV/co-GRA1 plasmid in four-well chamber slides fixed with methanol and acetone and incubated with 1% BSA (diluted in 1 × PBS) (Sigma-Aldrich, St. Louis, MO). The slides were then probed with the monoclonal antipolyhistidine antibody (Sigma) with a dilution of 1:200 for 1 h at room temperature, washed and then probed with antimouse IgG antibody conjugated with FITC produced in sheep (clone, His-1; Sigma) with a dilution of 1:500 for 1 h at room temperature. Thereafter, slides were washed and visualized using an immunofluorescence microscope (Zeiss Axiomat, Thornwood, NY).
Sodium dodecyl sulfate-polyacrylamide gels and Western blotting
HEK 293 cells, transfected with CMV/wt-GRA1 and CMV/co-GRA1 obtained from 10 cm-diameter culture dishes, were scraped from the dishes and counted with a hemocytometer. Equal amount of cells (approximately 6 × 10 6 cell per each sample) were washed thrice with 1 × PBS followed by several cycles of freezing and thawing. The lysate of cells were centrifuged at 10,000×g for 10 min. The amount of protein in the supernatant was determined using Coomassie Plus Protein Assay Reagent kit according to the manufacturer's protocol (Pierce, Rockford, Ill, USA). Serially diluted bovine serum albumin (BSA) was used as the reference. To compare the expression levels of CMV/wt-GRA1 and CMV/co-GRA1 in HEK 293 cell lysate, an equal amount of protein (approximately, 500 g protein per each sample) was separated by 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). To detect the immunoreactivity of the vaccine-induced antibodies, TAg was separated with 12% SDS-PAGE gel. The separated protein was transferred to a polyvinylidene difluoride (PVDF) transfer membrane (Immobilon-P, Millipore, Billerica, MA) and the membranes, which contained HEK 293 cell lysate, were probed with a 1:1000 dilution of the monoclonal anti-polyhistidine antibody (Sigma). To detect the immunoreactivity, the TAg-containing membranes were probed with 1:100 dilutions of four different serum sample pools, collected from three groups of vaccinated mice and control groups. Then the membranes were probed with a 1:1000 dilution of alkaline phosphatase-conjugated goat anti-mouse IgG (H + L) antibody (Bio-Rad). Thereafter, the blot was developed with 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and Nitro-BT (Fisher Scientific) diluted in alkaline phosphatasedeveloping buffer (0.1 M Na 2 CO 3 , pH 9.5, 0.1 M NaCl, 5 mM MgCl 2 ).
Protein expression and purification
E. coli Rosetta TM 2(DE3) pLysS chemically competent cells (Novagen, San Diego, CA) were transformed with pUET GRA1 [49] and grown in 1 l LB supplemented with 100 g/ml ampicillin and 50 g/ml chloramphenicol with vigorous shaking at 37 • C up to an optical density of 0.4, calculated at 600 nm. Then, the cells were induced with isopropyl-␤-d-thiogalactopyranoside (IPTG) to a final concentration of 1 mM with vigorous shaking at 20 • C overnight. The cells were centrifuged at 5000×g and the pellet was resuspended with 50 ml pre-chilled loading buffer (50 mM Tris-Cl pH: 7.5, 0.3 M NaCl and 0.5 mM CaCl 2 ). Then, the cells were disrupted with an M-110L microfluidizer processor (Microfluidics Corporation, Newton, MA) at a low temperature under internal pressure of 18,000 psi. The processed sample was centrifuged at 30,000 × g for 1 h at 4 • C. The clarified supernatant was filtered through 0.45 m filter (Nalgene, Rochester, NY). Purification of the protein was performed byÄKTA FPLC, a liquid chromatography system, which is controlled by UNICORN TM software, using a 5 ml HiTrap Chelating HP column (Amersham Biosciences, Pittsburgh, PA). Clarified supernatant was applied to the HiTrap column with loading buffer. Then, the column was washed with 100 mM imidazole containing 50 mM Tris-Cl, pH 7.5, 0.3 M NaCl, and 0.5 mM CaCl 2 buffer overnight at 4 • C. The recombinant GRA1 (rGRA1) protein was eluted by raising the imidazole concentration to 500 mM. The protein fractions were detected by UV280, confirmed by 12% SDS-PAGE, pooled, and concentrated with an Ultrafree-MC Centrifugal Filter Units (Millipore) at 4 • C. The protein was further purified by FPLC on a Superdex 200 column to remove excess endotoxin. The subsequent protein fractions were pooled, concentrated and quantitated. The molecular size of purified GRA1 protein was determined by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) (Applied Biosystems, Foster City, CA) using a sinapinic acid matrix. Three purified protein samples from three different preparations were analyzed.
Depletion and determination of endotoxin from purified protein
Detoxi-gel affinity column, which contains immobilized Polymyxin B, was used to remove endotoxin from the purified GRA1 protein sample according to the manufacturer's protocol (Pierce). The amount of endotoxin in the eluted sample was determined with a Limulus Ameobocyte Lysate Gel-Clot test using Pyrotell single test vials according to the manufacturer protocol (Associates of Cape Cod, East Falmouth, MA). The concentration of endotoxin-depleted, purified rGRA1 samples were calculated as described above and stored at −80 • C.
Vaccination and challenge
Three groups of female, 6 week-old, BALB/c mice (eight per each group) were vaccinated twice at three weeks interval with CMV/wt-GRA1, CMV/co-GRA1, and rGRA1 protein with PROVAX TM adjuvant (rGRA1-Provax). The plasmids were purified using an endol-free plasmid purification kit (EndoFree, Qiagen). During DNA vaccinations, 100 g plasmid was injected into both tibialis anterior muscle of anesthetized mice.
The rGRA1-Provax vaccine was formulated using rGRA1 protein and Provax adjuvant. Provax was prepared as described using Tween-80, pluronic L121 and squalane [50] . To evaluate the efficacy of rGRA1-Provax vaccine five mice were vaccinated intraperitoneally with 33 g of only rGRA1 protein as a control group.
Negative controls were composed of three groups of animals (eight per each) vaccinated with 100 g empty vector and 33 l of stabilized Provax emulsion. A group of naïve mice was also used as a control to evaluate the GRA1 vaccinations during the measurement of antigen specific proliferative response and cytokine determination. Tail bleeds were performed three weeks after each vaccination. Eight mice from each group were challenged intraperitoneally with 1 × 10 5 viable T. gondii RH strain tachyzoites nine weeks after the prime vaccination.
Measurement of humoral antibody response using protein microarray analysis
Protein microarray chips were prepared as described [48, 51] . Briefly, 15 l purified rGRA1 (2.5 mg/ml) printed onto nitrocellulose-coated FAST TM glass slides (Schleicher & Schuell, Keene, NH) using an OmniGrid 100 microarray printer (Genomics Solutions, Ann Arbor, MI). The slides were probed with mouse serum samples diluted in Protein Array Blocking Buffer (PABB, Schleicher & Schuell) which were obtained three weeks after the first and second vaccinations. Proteome slides were washed with 1 × TBS-T buffer (0.5% Tween-20, 20 mM Tris-HCl, 0.5 M NaCl) and complexed antibodies were visualized after incubating the slides with Cy3-conjugated IgG antibody (Jackson ImmunoResearch, West Grove, PA). The proteome slides were washed with 1 × TBS-T and 1 × TBS buffers before scanning in a ScanArray 4000 laser confocal scanner (GSI Lumonics, Billerica, MA). The fluorescence intensity (FI) of each spot was quantified using QuantArray software (GSI Lumonics). Samples were considered positive if the FI of the 1/50-diluted vaccinated animal serum sample exceeded the FI + 5 S.D. of the 1/50-diluted serum sample of the animal injected with the corresponding negative control for the particular group of vaccination.
Determination of IgG subclass antibody response using protein microarray analysis
Analysis of serum anti-rGRA1 IgG1 and IgG2a subclass antibodies in vaccinated mouse serum samples were performed by protein microarray analysis as described above. After the slides were probed with 1/50-diluted mouse serum samples, the slides were incubated with Cy3-conjugated IgG1 and IgG2a antibody (Jackson ImmunoResearch) at 1/200 dilution for 2 h. Fluorescence intensities were analyzed using ScanArray 4000 laser confocal scanner and QuantArray software (GSI Lumonics) as described above.
Measurement of antigen-specific proliferative immune response
Nine weeks after the prime vaccination, spleens were surgically removed from euthanized mice (three mice per group). Single-cell suspensions of splenocytes were prepared as described [28] . Aliquots of 5 × 10 5 viable splenocytes in 100 l growth medium [1 × RPMI 1640 supplemented with 10% FCS, 55 M 2-mercaptoethanol (Invitrogen-Gibco), 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acid, 2 mM l-glutamine, penicillin (100 U/ml) and streptomycin (100 g/ml) (Cellgro)] were plated in triplicate into each well of 96 well round bottom plate. Before the stimulation of spleen cells, endotoxin-depleted purified rGRA1 was incubated with polymyxin B to a final concentration of 50 g/ml for 1/2 h. Cells were stimulated with 0.6-50 g/ml purified rGRA1 protein or stimulated with a concentration of 15 g/ml unrelated vaccinia virus recombinant H3L (rH3L) control protein. As a positive control in all experiments, cells were incubated with Concanavalin A at a final concentration of 10 g/ml. As a negative control, only 200 l growth medium was used. Cultures of cells in a final volume of 200 l in each well were incubated 72 h at 5% CO 2 and 37 • C and then pulsed with 1 Ci of 3 [H]-thymidine (Perkin Elmer Life and Analytical Sciences, Boston, MA) per well, diluted in 50 l growth medium, during the last 16 h. Cells were harvested using a cell harvester (TOMTEC, manual harvester 96, Mac IIM, Hamden, CT) and glass filter paper (Wallac, Turku, Finland). The radioactivity was quantified by liquid scintillation counting (BETA plate liquid scintillation counter (Wallac). The results are expressed as the stimulation index (SI), which is calculated as the mean counts per minute (cpm) of cells stimulated with rGRA1 protein divided by the mean cpm of controls.
Cytokine determination
Splenocytes were prepared as described above. Cell-free supernatant was collected and assayed for IL-4 activity at 24 and 72 h and gamma interferon (IFN-␥) activity at 72 h. The concentration of IL-4 and IFN-␥ were determined using ELISA kits (eBioscience, San Diego, CA) according to the manufacturer protocol. The sensitivity limit for the ELISA was deduced from the standard curves after serial dilution of the recombinant mouse IFN-␥ and recombinant mouse IL-4 standards provided by the kit. Values higher than 100 pg/ml and 10 pg/ml, calculated from the results with naïve mice, were considered positive for IFN-␥ and IL-4, respectively.
Statistical analysis
Data obtained during the study were processed using Prism 3.03 (GraphPad, San Diego, CA). A two-tailed unpaired t-test or one-way analysis of variance with 95% confidence interval was used to determine the significance between the vaccination groups. Kaplan-Meier survival curves were constructed to illustrate protection from lethal toxoplasmosis. Results of humoral immune response, cellular immune response and survival time were expressed as mean ± standard deviation (S.D.).
Results

PCR assembly of co-GRA1 and in vivo recombination cloning
Wild type GRA1, without the signal peptide, is 498 bp in length and has a 52% G/C content. To optimize the GRA1 gene for expression in mammalian cells, 19 codons were excluded, six codons were reduced in frequency, and 23.1% of the codons were changed ( Table 1 ). The final co-GRA1 gene has a 63% G/C content. The codon usage of Homo sapiens was used to measure the codon adaptation index (CAI) of wt-GRA1 and co-GRA1 codons. The CAI of wt-GRA1 is 0.697 and the CAI of co-GRA1 is 0.917.
The self-assembly of the co-GRA1 gene was performed with two PCR and TOPO cloning reactions. The primer extension and PCR amplification products of the over lapping CODA-designed DNA oligonucleotides to produce the 237 bp, and two 196 bp, product intermediate gene fragments are shown in Fig. 1, lanes 2-4, respectively. The 531 bp, fulllength, co-GRA1 primer extension and PCR product of these three over-lapping intermediate gene fragments is shown in Fig. 1, lane 1 . Then, wt-GRA1 and co-GRA1 were isolated from pUET GRA1 and pCR-Blunt II TOPO vectors, respectively and rapidly cloned into the CMV vector. The resulting kanamycin-resistant E. coli cell clones contained either the CMV/wt-GRA1 plasmid with the directionally inserted inframe wt-GRA1 gene or the CMV/co-GRA1 plasmid with the co-GRA1 gene.
In vitro transfection studies
To determine the in vitro protein expression levels of co-GRA1 and wt-GRA1 in mammalian cells, human embry- onic kidney (HEK) 293 cells were transfected with the CMV/wt-GRA1 and CMV/co-GRA1 plasmids. A CMV vector containing green fluorescent protein (CMV/GFP) was used as a positive control and an empty CMV vector, as a negative control (data not shown). Expression levels of co-GRA1 and wt-GRA1 were determined by immunofluorescence and Western blotting using anti-polyhistidine antibody. The results in Fig. 2 demonstrate that the expression level of rGRA1 in HEK 293 cells is clearly higher in the HEK 293 cells transfected with the CMV/co-GRA1 compared to HEK 293 cells transfected with the CMV/wt-GRA1.
Protein expression, purification, and characterization
The expression of rGRA1 was induced with 1 mM IPTG when the growing cells reached an optical density of 0.4 at 600 nm. The cells were harvested after 16 h, lysed, and processed. The rGRA1 protein was purified in two steps, first on a HiTrap Ni 2+ Chelating HP column and then on a Superdex 200 column. The protein purity was ascertained by SDS-PAGE and the results are shown in Fig. 3 . The purification protocol yielded 2.5 mg of purified rGRA1 from 1 l of cell GCC  GAA  GGC  GGC  GAC  AAC  CAG  TCG  AGC  GCC  GTC  TCA  GAT  CGG  GCG  TCT  CTC  TTT  GGT  TTG  co-GRA1  GCT  GAG  GGA  GGA  GAC  AAC  CAG  AGC  TCT  GCT  GTG  TCC  GAT  CGC  GCC  TCT  CTG  TTC  GGC ACT  ATG  AAA  AGC  ATG  CAG  AGG  GAC  GAG  GAC  ATT  TTC  CTT  CGT  GCG  TTG  AAC  AAA  GGC  GAA  co-GRA1  ACC  ATG  AAG  AGC  ATG  CAG  CGC  GAC  GAG  GAC  ATC  TTT  CTG  CGG  GCT  CTG  AAC  AAG  GGC  GAG  Diff(12) ..C . . . ACA  GTA  GAG  GAA  GCG  ATC  GAA  GAC  GTG  GCT  CAA  GCA  GAA  GGG  CTT  AAT  TCG  GAG  CAA  ACC  co-GRA1  ACC  GTG  GAG  GAA  GCC  ATC  GAG  GAC  GTC  GCC  CAG  GCC  GAG  GGG  CTC  AAC  AGC  GAG  CAG  ACC  Diff(15) . CTG  CAA  CTG  GAA  GAT  GCA  GTG  AGC  GCG  GTG  GCG  TCT  GTT  GTT  CAA  GAC  GAG  ATG  AAG  GTG  co-GRA1  CTC  CAG  CTG  GAA  GAT  GCC  GTG  AGC  GCC  GTG  GCC  AGC  GTG  GTG  CAG  GAC  GAG  ATG  AAG  GTG  Diff(11) .
The first row displays the wt-GRA1 gene sequence; the second row, the CODA-optimized GRA1 gene sequence; and the third row, the modified bases in each codon. Although the codons are changed, the amino acid sequence of the GRA1 protein remains the same, as shown in the fourth row. Fig. 3 . SDS-PAGE analysis of purified rGRA1 loaded into each well from concentrations of 100 through 300 g (lanes 1 through 5) . The protein ladder is from QuantPro (Expression Technologies, San Diego, CA).
culture. On SDS PAGE and on Western blots using by antipolyhistidine monoclonal antibody, the purified rGRA1 had an apparent molecular mass of 26 kD. The calculated molecular mass of the rGRA1, expressed from the 669 bp ORF, was only 24,085. To resolve the discrepancy, purified rGRA1 from three separate batches were analyzed by MALDI-TOF Mass spectroscopy (MS) and each showed a peak at 24,120.
Humoral immune response to GRA1 vaccines
The rGRA1 protein has been reported to strongly bind T. gondii-specific antibodies in human sera [52] . Several types of experiments were carried out to determine the humoral immune response to each type of vaccine candidate. In the first experiment, total T. gondii parasite lysate was probed with a pool of serum samples obtained from each group of vaccinated BALB/c mice. Each type of vaccine induced a strong antibody response against a 24 kD protein in T. gondii lysate, as detected by Western blots shown in Fig. 4 . No antibody response was detected in the control group, in which mice were vaccinated with Provax or an empty vector.
In the second set of experiments, serum samples from each group of vaccinated mice were tested for the presence of antiGRA1-specific IgG antibodies. The negative controls consisted of sera pools of mice vaccinated with Provax for the rGRA1-Provax group or empty vector for the DNA vaccine groups. In all vaccination groups, the amount of IgG antibodies significantly increased after the booster vaccination (P < 0.01). Fig. 5 summarizes the fluorescence intensity data collected for each group of vaccinated mice, after the prime and the boost vaccinations. Among all vaccination groups, the highest humoral immune response was achieved after boosting with rGRA1-Provax. The CMV/co-GRA1 vaccine yielded a somewhat higher antibody response than the CMV/wt-GRA1-DNA vaccine.
In the final evaluation of the humoral immune response, the frequency of the IgG1/IgG2a polarization was determined as a preliminary indication of whether one or more of the GRA1 vaccines induced a Th1 or Th2 response. The results are shown in Fig. 6 . Of eight mice vaccinated with rGRA1-Provax, six showed a strong IgG1 response as well as a weaker IgG2a response; two mice experienced a nearly equivalent, but weak IgG1 and IgG2a response (Fig. 6B) . In the DNA vaccination groups, four displayed a stronger IgG2a response; three showed a stronger IgG1 response, and one had a comparable IgG1 and IgG2a response (Fig. 6C and D) . Overall, the GRA1 DNA vaccinations induced a similar pattern of Th1 and Th2 polarity, with a slight bias towards a Th1 response. Furthermore, to evaluate the contribution of the adjuvant to the observed immune responses, five mice were vaccinated with only rGRA1 protein. Similar to a previous study [31] , there was a weak IgG1 and IgG2a response slightly biasing towards IgG1 response to the rGRA1 protein in the absence of an adjuvant (Fig. 6E) . Thus, Provax adjuvant significantly improved the protective IgG2a response to rGRA1 protein (P = 0.0029). All controls, containing empty vector and Provax, adjuvant, had no detectable immune response to either IgG1 or IgG2a (Fig. 6F) .
Cell-mediated immune response to rGRA1 vaccines
Splenocytes from individual immunized mice were stimulated in vitro with purified rGRA1 protein and with the mitogen, Con A, as well as with unrelated vaccinia virus rH3L protein as controls. Incorporation of [ 3 H]-thymidine was used to measure lymphocyte proliferation achieved by rGRA1 vaccines. As Table 2 reports, in the lymphoproliferation assays, the T-cell stimulation index (SI) was significantly higher with the mice vaccinated with rGRA1-Provax protein vaccine compared to the CMV/co-GRA1 vaccinated mice and CMV/wt-GRA1 vaccinated mice (P = 0.0007). How- Table 2 Lymphoproliferation and cytokine production of BALB/c mice vaccinated with rGRA1-Provax, CMV/co-GRA1 and CMV/wt-GRA1
Vaccine candidates
Stimulation index a Cytokine production (pg/ml) b IFN-␥ IL-4 rGRA1-Provax 4.7 ± 0.2 1502 ± 301 28 ± 0 CMV/co-GRA1 3.4 ± 0.6 565 ± 22 16 ± 4 CMV/wt-GRA1 2.8 ± 0.4 481 ± 25 15 ± 2 a As described in methods, the stimulation index is the ratio of the mean counts per minute (cpm) of spleen cells stimulated with varying concentrations of rGRA1 to the mean cpm of controls.
b The culture supernatants were assayed for cytokine production. Values for IFN-␥ and IL-4 were obtained from 72 h culture.
ever, there was no statistical difference in lymphoproliferative response in mice vaccinated with either the CMV/wt-GRA1 or the CMV/co-GRA1 DNA vaccines (P = 0.1). In the controls, the mean cpm, 2607 ± 349, of the non-stimulated cells from GRA1-vaccinated groups was similar to the mean cpm of 2586 ± 406 from naïve mice spleen cells stimulated with rGRA1 and to the mean cpm of 2866 ± 403 GRA1-vaccinated mice spleen cells stimulated with unrelated vaccinia virus rH3L protein. Mice vaccinated with only rGRA1 protein showed a slightly higher SI compared to control mice (data not shown). For all groups, stimulation with Con A displayed counts above 50,000 cpm. In addition, spleen cells from all experimental and control groups proliferated to comparable levels in response to Con A and showed no response to vaccinia virus rH3L protein.
As a measure of the Th1 or Th2 immune response, the production of IFN-␥ and IL-4 in spleen cells of vaccinated mice and control groups were determined by ELISA (Table 2) . After stimulating with rGRA1, the production of IFN-␥ at 72 h was significantly higher in mice vaccinated with the rGRA1-Provax vaccine compared to mice vaccinated with either DNA vaccine (P = 0.0083). The IFN-␥ levels were only slightly higher in the mice vaccinated with CMV/co-GRA1, compared to mice vaccinated with CMV/wt-GRA1 (P = 0.5). The IFN-␥ levels in mice vaccinated with Provax adjuvant was 89 ± 12 pg/ml and were below the cut-off value. The splenocytes from mice vaccinated with empty vector showed nonspecific IFN-␥ production at low levels of 243 ± 48 pg/ml. IL-4 levels were assayed in cell culture supernatants at two time points after stimulation with rGRA1. IL-4 levels were not detected in any animal group at 24 h (data not shown). In contrast, a significant increase in IL- Fig. 7 . Survival profiles of vaccinated BALB/c mice against lethal toxoplasmosis. All mice were challenged with 1 × 10 5 T. gondii RH strain tachyzoites nine weeks after the prime vaccination. T. gondii tachyzoites were administered to mice vaccinated with rGRA1-Provax ( ), CMV/co-GRA1 (×), CMV/wt-GRA1 ( ), and the control groups, empty vector ( ) or Provax ( ).
4 was detected after 72 h of stimulation in mice vaccinated with rGRA1-Provax compared to naïve animals or the control groups vaccinated only with Provax (P < 0.0001). The IL-4 levels produced by mice vaccinated with either DNA vaccine were only slightly higher than mice vaccinated with naïve mice or empty vector. IL-4 production in control groups of mice vaccinated with empty vector and Provax adjuvant was 12 ± 2 and 13 ± 2 pg/ml, respectively. Mice vaccinated with only rGRA1 protein achieved cytokine levels slightly above cut-off value (data not shown). IL-4 and IFN-␥ levels produced by spleen cells obtained from GRA1 vaccinations after stimulation with unrelated vaccinia virus rH3L protein was below the cut-off value (data not shown). Taken together, all vaccines induced higher IFN-␥ levels compared to IL-4 levels, with the rGRA1-Provax vaccine producing the highest IFN-␥ levels among all groups.
Protection against lethal toxoplasmosis
Protection against lethal toxoplasmosis was compared in vaccinated BALB/c mice using T. gondii RH strain. Animals were intraperitoneally injected with 1 × 10 5 RH strain tachyzoites nine weeks after the prime vaccination. After challenging in the control groups, mice vaccinated with only Provax or empty CMV vector survived 5.1 ± 0.6 and 5.3 ± 0.5 days, respectively. Survival prolonged significantly in groups vaccinated with rGRA1-Provax, CMV/co-GRA1, and CMV/wt-GRA1 compared to controls (P < 0.0001). Mice vaccinated with rGRA1-Provax survived approximately 9.8 ± 2.3 days, which was slightly higher than the mice vaccinated with CMV/wt-GRA1 (8.5 ± 0.8 days) and CMV/co-GRA1 (9.1 ± 1 days) (P = 0.2). Nine days after challenging, 50% of mice vaccinated with rGRA1-Provax were alive compared to 25% of CMV/co-GRA1 and 12.5% CMV/wt-GRA1 vaccinated mice. Eleven days after challenging, among three vaccination groups, 25% of mice vaccinated with rGRA1-Provax were alive and none of the CMV/co-GRA1 and CMV/wt-GRA1 DNA vaccinated mice was alive. Survival prolonged approximately 1.6 times in CMV/wt-GRA1 vaccinated group, 1.7 times in CMV/co-GRA1 vaccinated group and 1.9 times in rGRA1-Provax vaccinated group compared to controls. Overall, the rGRA1-Provax vaccination prolonged survival in 12.5% of mice up to 14 days, almost doubled the survival time compared to controls and thus, afforded the most protection among all vaccination groups. The results are summarized in Fig. 7 .
Discussion
Although vaccine research against toxoplasmosis shows promise, much effort is yet required to develop a safe and effective T. gondii vaccine with long-lasting effects. To date, the only commercial vaccine, which has been developed using live tachyzoites from the S48 T. gondii strain, is used for protection against toxoplasmosis in sheep [53] . The vaccine is not widely used as a consequence of reactivation of the live tachyzoites to the pathogenic form, short shelf life, and high cost [6] . To circumvent the negative features, current research is focused on developing safe vaccines from DNA segments or from antigenic protein(s) of T. gondii.
GRA1 is considered to be a promising vaccine candidate because GRA1 DNA vaccines elicit immune responses as well as afford protection in rodent and livestock models [8, [26] [27] [28] . Purified rGRA1 protein vaccines have also found to be immunogenic, however protection studies in animal models haven't been conducted yet [8, 27, 31] . Thus, the present study focuses on the immunogenicity and protection potency of three types of GRA1-derived vaccines candidates. The GRA1 vaccines in this study include a wild type GRA1 DNA vaccine (CMV/wt-GRA1), a GRA1 DNA vaccine that has been codon optimized for expression in mammalian cells (CMV/co-GRA1), and a GRA1 recombinant protein vaccine adjuvanted with Provax (rGRA1-Provax).
DNA vaccination strategy has become popular in 1990s. Intramuscular injection of DNA vaccines mostly induce dom-inant Th1 type immune response as shown by the induction of IgG2a antibody response, increased levels of IFN-␥ and small quantities of IL-4 production [54] . One of the limiting factors in inducing strong immune response after the administration of wild type DNA vaccines is the low (picogram to nanogram) quantities of protein expression in vivo [54] . Another factor for suboptimal protein expression occurs when the codon usage of the target gene in a DNA vaccine is different from the mammalian cells. The presence of rare codons in cloned genes affects mRNA and plasmid stability as well as protein expression level. The excessive presence of rare codons can result in ribosome stalling, slow translation, and translation errors. In some cases, rare codons inhibit protein synthesis and cell growth [55] . Several approaches have been used successfully to compound these problems. One of them is to use cytomegalovirus (CMV) promoter in DNA vaccines to increase gene expression in host cells [54] . The other common strategy is to remove rare codons by codon optimization to increase the protein expression. For this purpose, in the present study, a CMV promoter containing plasmid and codon optimization strategies were used to increase the efficacy of wild type GRA1 DNA vaccination. To optimize the codon usage of wild type GRA1 for expression in mammalian systems, the novel algorithm for codon optimization, termed CODA was used. CODA includes codon substitutions to facilitate the error-free self-assembly of the gene from DNA oligonucleotides in a few simple steps [56] . In the present study, after the assembly of co-GRA1 and construction of CMV/co-GRA1 plasmid, a comparison of CMV/co-GRA1 and CMV/wt-GRA1 protein expression levels in HEK 293 cells demonstrated that CMV/co-GRA1 expressed rGRA1 protein clearly higher than CMV/wt-GRA1.
Immune protection against T. gondii in mice is primarily correlated with IFN-␥ level [3] [4] [5] . IgG2a production from B cells is under the influence of Th1 response or low IFN-␥ secretion [4] thus, a vaccine candidate against toxoplasmosis has to primarily increase IgG2a and especially IFN-␥ levels. In the present study, both types of DNA vaccines elicited a significant humoral and cellular immune response as well as increased survival rates in mice infected with the lethal RH tachyzoites compared to controls. After prime and boost vaccinations, CMV/co-GRA1 vaccine yielded a higher IgG antibody response than the CMV/wt-GRA1 vaccine. During the evaluation of subgroup IgG antibody response, 50% of both DNA vaccines have polarized towards Th1 response. In the previous GRA1 DNA vaccination studies, the VR1020 plasmid encoding GRA1 achieved similar results [26, 28] ; however, the same plasmid mostly produced an IgG1/Th2 response [8] . During the evaluation of antigen specific lymphocyte proliferation and IFN-␥ production of spleen cells, stimulated with endotoxin depleted rGRA1 protein, CMV/wt-GRA1 and CMV/co-GRA1 DNA vaccinations showed significant increase compared to controls which were similar in the previous studies using the T. gondii lysate antigens for the stimulation of spleen cells [26, 28] . In addition, an increase in IL-4 levels was obtained from the spleen cells stimulated 72 h compared to controls. An increase in IL-4 levels, which was not detected in previous studies, explains the correlation between the IgG1 response and IL-4 response obtained from DNA vaccinations. The reason of the IgG1/Th2 and IgG2a/Th1 response variation between vaccinated animals observed in the present study and previous DNA vaccination studies is not yet known; however, the site of antigenic protein expression (i.e., myocytes versus dendritic cells/skin cells), differential stimulation of innate immune system, or the immune system of animal used in the experiments may be responsible for this variation [54] .
During the evaluation of protection potency, CMV/co-GRA1 vaccine was slightly better than CMV/wt-GRA1 vaccine, which was comparable to immune responses elicited by the vaccines. Nine days after challenging 25% of CMV/co-GRA1 and 12.5% CMV/wt-GRA1 vaccinated mice were alive and survival was prolonged in BALB/c mice 1.6 and 1.7 times, respectively compared to controls that survived approximately five days after challenging. In two consecutive studies, VR1020 plasmid encoding rGRA1 protein was evaluated in C3H, BALB/c and C57BL/6 mice with nonstandardized doses of T. gondii IPB-G and 76 K strain cysts [26, 28] . In the BALB/c mice group, protection after challenging with 200 and 50 cysts of T. gondii IPB-G strain was 0% and 70% whereas protection in controls mice was 0% and 80%, respectively. In the C3H mice group protection after challenging with 50 cysts of IPB-G strain and 50 cysts of 76 K strain was 70% and 90% whereas protection in the control groups were 10% and 50%, respectively [28] . In the following study, two groups of four C3H mice were challenged with 40 cysts of IPB-G strain and protection was 75% and 100% in the vaccinated groups and 0% and 25% in the control groups, respectively [26] .
In the literature, similar to the present study, protection was determined using lethal doses of RH strain tachyzoites and among these, the best survival was conferred by SAG1 encoding plasmid in C3H and BALB/c mice groups in which the protection was 100% and 80% compared to 30% and 20% protection in control groups, respectively [23] . Other studies using ROP2 or SAG1 single gene DNA vaccinations did not increase survival significantly [12, 18] ; however, ROP2-SAG1 cocktail vaccine and DNA vaccine encoding T. gondii genomic library increased survival up to four times compared to controls [12, 13] . Overall, the elicited immune response, as determined by IgG1, IgG2a, IFN-␥ and IL-4 levels, as well as the protection potency was somewhat higher for the CMV/co-GRA1 DNA vaccine than for the CMV/wt-GRA1 DNA vaccine and mammalian codon-optimized GRA1 DNA vaccine showed immunogenicity and protection comparable to previous vaccination studies. However, immunogenicity and protection potency of codon-optimized GRA1 DNA vaccine did not increase, similar to the results obtained from in vitro studies. The reason might be that the 40% increase achieved by codon-optimized GRA1 DNA vaccine in vitro may not be enough to significantly increase the immune response and protection because the low (only picogram to nanogram) quantities of protein expression in vivo is the most important limiting factor of DNA vaccines in inducing strong immune response [54] . As a result, codon-optimization of GRA1 marginally improved the properties of the GRA1 DNA vaccine.
The rGRA1 protein vaccine was prepared from recombinant GRA1 purified to homogeneity, resulting in an overall yield of 2.5 mg rGRA1 protein per liter of cultured E. coli cells. Although rGRA1 protein has a calculated molecular mass of 24,085, the recombinant protein migrates as a 26 kD protein on SDS-PAGE, an anomaly also observed in other laboratories. To resolve the discrepancy, the molecular mass of rGRA1 protein was determined by MALDI-TOF mass spectroscopy to be 24,120. GRA1 is located in the electrondense secretory organelles, which continuously release their content into the parasitophorous vacuole (PV) during the intracellular development of T. gondii. GRA1 functions as a calcium-binding protein and is found in a soluble form in the lumen and network of the PV during invasion of the host cell [57, 58] . Calmodulin protein is an EF-hand Ca 2+ binding protein [59, 60] . Calmodulin protein demonstrates altered migration on SDS PAGE gels upon Ca 2+ binding [61] [62] [63] . Recombinant and naïve GRA1 protein has two EF-hand Ca 2+ binding sites also [57, 58] . Thus, the Ca 2+ binding property of rGRA1 protein might be causing the discrepancy similar to the one detected in calmodulin protein.
The immunogenicity of rGRA1 protein was evaluated in previous studies, however protection potency and cellular immune response of an adjuvanted rGRA1 protein vaccine was not evaluated comprehensively [8, 27, 31] . To formulate the protein vaccine for the present research, purified and endotoxin depleted rGRA1 protein was adjuvanted to Provax, which is known to be a strong inducer of Th1 cytokine and antigen-specific CD8 lymphocyte production. Indeed, Provax is prepared by mixing previously known strong adjuvants squalane and pluronic L121 to Tween-80 [32, 33, 64] . Adjuvants have been reported to increase the immunogenicity of protein vaccines [64] . A similar observation was made in the experiments reported herein. Importantly, the Provax adjuvant significantly enhanced the humoral and cellular immune response to the rGRA1 protein vaccine. As shown in results, the highest IgG antibody response was achieved after boosting with rGRA1-Provax among all GRA1-derived vaccinations. rGRA1-Provax induced a strong IgG1 response and a weaker, but still prominent, IgG2a response. The rGRA1-Provax vaccination increased IFN-␥ production approximately three times more than the GRA1 DNA vaccines. Consistent with IgG1 response, small quantities of IL-4 levels were detected after 72 h stimulation of spleen cells with endotoxin depleted rGRA1 protein. Overall, the Provax adjuvant significantly enhanced the protective IgG2a and IFN-␥ response to the rGRA1 protein. Consistent with the strong immune response, the rGRA1-Provax vaccine nearly doubled the survival rate in mice against lethal T. gondii infection. Vaccination studies using purified recombinant proteins of T. gondii are few compared to DNA vaccinations. Recombinant SAG1 protein adjuvanted with alum increased survival 44% compared to 20% in the control group after challenge with lethal doses of RH strain tachyzoites [24] and contrarily, in another vaccination trial, the mortality in mice after vaccination with adjuvanted SAG1 protein was significantly higher than the controls [30] .
Thus, the present study comprehensively evaluates immunogenicity and protection potency of an rGRA1 protein vaccine for the first time and compares the results with that of the two GRA1 DNA vaccines. Overall, the rGRA1-Provax vaccine appears to be somewhat better in all measured immune responses, particularly the IFN-␥ level which is primarily correlated with immune protection against T. gondii in mice [3, 4] . As a result of this strong immune response, the protection potency of the rGRA1-Provax vaccine in the BALB/c mice against the RH strain T. gondii infection was also better than the two GRA1 DNA vaccines. The reason for the increased immunogenicity and protection of the recombinant GRA1 protein vaccine is not yet clear and requires additional experiments to determine whether the outcome would be different by varying the protein concentration or the type of the adjuvant. Consequently, commercially available successful recombinant protein vaccines against Hepatitis B Virus and Human papillomavirus and the immunogenicity of the adjuvanted rGRA1 protein vaccine shown in the present study, address the importance of developing recombinant protein vaccine strategies against toxoplasmosis.
